Suzhou Basecare Medical Corporation Limited (2170) Fair Value & Analysis
Healthcare · HK · Market cap HK$383M (≈ $48.8M)
What is Suzhou Basecare Medical Corporation Limited really worth?
Below-average quality, and trading another 133% above our fair value of HK$0.5900.
As of Aug 27, 2026, the fair value of Suzhou Basecare Medical Corporation Limited is HK$0.5900 per share against a price of HK$1.38, so the fair value sits 57% below the price. A model estimate blended from multiple valuation models, recalculated regularly.
Risks
Fair value as of: Aug 27, 2026
From 1 valuation models · updated 10 days ago
Share price −1.8% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (HK$0.7300). The favourable scenario is already priced in.
- Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range (HK$0.3900 to HK$0.7300) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 27, 2026.
How to read this chart
60‑month range HK$1.28 – HK$28.20 · fair‑value band HK$0.3900 – HK$0.7300 · the HK$1.38 price screens above the HK$0.5900 fair value. Dashed = 300-day average. As of Aug 27, 2026.
Analysis
Suzhou Basecare Medical Corporation Limited (2170) currently trades at HK$1.38, while our model-based Fair Value estimate is HK$0.5900, implying the stock looks roughly 133.0% overvalued today. The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector. How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Over the trailing twelve months, Suzhou Basecare Medical Corporation Limited generated revenue of HK$233M at a net margin of −95.8%. Revenue declined 24.3% year over year. It earns a return on equity of −21.5%. The balance sheet holds a net cash position of HK$75.7M. Fundamentals as of Aug 27, 2026
Our scenario range runs from HK$0.3900 (bear case) to HK$0.7300 (bull case); at HK$1.38, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 68% below its 52-week high and 12% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −34% fair-value upside, at −57%, 2170 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 1 models by family
Notify me when 2170 reaches fair value
Put 2170 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 27, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 42 · Market factors (momentum, volatility) 29
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Suzhou Basecare Medical Corporation Limited, an investment holding company provides genetic testing solutions for assisted human reproduction in the People's Republic of China and Australia.
Full company description
Suzhou Basecare Medical Corporation Limited, an investment holding company provides genetic testing solutions for assisted human reproduction in the People's Republic of China and Australia. The company offers pre-implantation genetic test kits, including PGT-A kit to detect aneuploidy; PGT-M kit to detect single-gene or monogenic defects in pre-implantation embryos; and PGT-SR kit to detect chromosome structural rearrangements, which are common causes of recurrent miscarriage, implantation failures, and birth defects. It also provides DA500, a high-throughput gene sequencer that provides users with sequencing options; DA5000 high-throughput gene sequencer which provides one-stop genetic laboratory solution for assisted reproductive centers; BS1000C, a high-throughput automated sample preparation system; PGT-A, PGT-M, and PGT-SR analysis software; Geri, a Time-Lapse Incubator to provide safe and stable culture conditions for embryo culturing; and Gems, a range of assisted reproductive laboratories fluids. In addition, the company offers BCT38, a liquid nitrogen storage dewar with a digital management system; BSG800A and BSG800C, a cryopreservation system; BKA210, a Sperm quality analyzer; Self Sperm Testing Device; Gavi, an automated vitrification instrument for the process of freezing embryos and eggs in the IVF automated vitrification; Intelligent assisted reproduction management system (iARMS), an assisted reproduction management system that runs through the reproductive cycle and covers patient medical records, medical diagnosis, and treatment plans. Further, it provides marketing services; and engages in the research and development of testing devices, instruments and consumables, as well as software for testing devices and instruments. The company serves hospitals and reproductive clinics. It sells its products through distributors. Suzhou Basecare Medical Corporation Limited was incorporated in 2010 and is headquartered in Suzhou, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Suzhou Basecare Medical Corporation Limited reported revenue of 233M CNY in FY2025 versus 107M CNY in FY2021, a compound +21.4%/yr. Reported net income was −223M CNY in FY2025.
2170 screens 133% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 27, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $112.47 | $74.79 | −34% |
| Stryker Corporation SYK | $322.12 | $186.28 | −42% |
| Medtronic plc MDT | $89.97 | $65.57 | −27% |
| Boston Scientific Corporation BSX | $46.84 | $30.73 | −34% |
| Edwards Lifesciences Corporation EW | $89.78 | $41.02 | −54% |
| Siemens Healthineers AG SHL | €39.52 | €33.87 | −14% |
| DexCom, Inc DXCM | $90.82 | $38.95 | −57% |
| GE HealthCare Technologies Inc GEHC | $74.82 | $64.13 | −14% |
| Koninklijke Philips N.V PHIA | €23.69 | €14.36 | −39% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥150.63 | ¥147.63 | −2% |
Compare Suzhou Basecare Medical Corporation Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Suzhou Basecare Medical Corporation Limited (2170) overvalued or undervalued?
What is the fair value of 2170?
What is the quality score of 2170?
What is the price target for Suzhou Basecare Medical Corporation Limited (2170)?
What is the Suzhou Basecare Medical Corporation Limited stock forecast for 2026?
What is the revenue of Suzhou Basecare Medical Corporation Limited (2170)?
What is the net profit margin of 2170?
Watch Suzhou Basecare Medical Corporation Limited in the live analysis
One click puts Suzhou Basecare Medical Corporation Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.